About: Considerations on Biologicals for Patients with allergic disease in times of the COVID‐19 pandemic: an EAACI Statement

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Considerations on Biologicals for Patients with allergic disease in times of the COVID‐19 pandemic: an EAACI Statement Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Considerations on Biologicals for Patients with allergic disease in times of the COVID‐19 pandemic: an EAACI Statement
Creator	Bossios, Apostolos Pfaar, Oliver Palomares, Oscar Akdis, Cezmi Kowalski, Marek Agache, Ioana Bousquet, Jean Chaker, Adam Eiwegger, Thomas Jutel, Marek Matucci, Andrea Untersmayr, Eva Vultaggio, Alessandra Boyman, Onur Bavbek, Sevim Chan, Susan Chatzipetrou, Alexia Firinu, Davide Kauppi, Paula Kothari, Akash Akdis, Mubeccel Antonioskolios, Ludgerklimek, Rogala, Barbara Wojciechfeleszko,
Source	Medline; PMC
abstract	The outbreak of the SARS‐CoV‐2‐induced Coronavirus Disease 2019 (COVID‐19) pandemic re‐shaped doctor‐patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant numberof the patients are on treatment with biologicals and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS‐CoV‐2 is not known. Severe COVID‐19 patients may experience a “cytokine storm” and associated organ damage characterized by an exaggerated release of proinflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti‐inflammatory cytokines and type 2 responses. This expert based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID‐19 with studies focusing on severe allergic phenotypes lacking. At present, non‐infected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self‐application. In case of an active SARS‐CoV‐2 infection, biological treatment needs to be stopped until clinical recovery and SARS‐CoV‐2 negativity is established and treatment with biologicals should be re‐initiated. Maintenance of add‐on therapy and a constant assessment of disease control, apart from acute management is demanded.
has issue date	2020-06-05(xsd:dateTime)
bibo:doi	10.1111/all.14407
bibo:pmid	32500526
has license	no-cc
sha1sum (hex)	e324e1ab3ad17d8c71fa83e1320223490da44f88
schema:url	https://doi.org/10.1111/all.14407
resource representing a document's title	Considerations on Biologicals for Patients with allergic disease in times of the COVID‐19 pandemic: an EAACI Statement
has PubMed Central identifier	PMC7300800
has PubMed identifier	32500526
schema:publication	Allergy
resource representing a document's body	covid:e324e1ab3ad17d8c71fa83e1320223490da44f88#body_text
is schema:about of	named entity 'EAACI' named entity 'exaggerated' named entity 'SARS-CoV-2' named entity 'biologicals' named entity 'optimal' named entity 'Disease' named entity 'provide' named entity 'COVID-19' named entity 'induced' named entity 'proinflammatory' named entity 'type 2' named entity 'antiviral activity' named entity 'biologicals' named entity 'phenotypes' named entity 'type 2' named entity 'allergy/immunology' named entity 'type 3' named entity 'based' named entity 'potential' named entity 'type 1' named entity 'pandemic' named entity 'biologicals' named entity 'type 1' named entity 'immunological' named entity 'Coronavirus Disease 2019' named entity 'inhalation' named entity 'pathogenesis' named entity 'anti-viral' named entity 'anti-IgE' named entity 'type 1' named entity 'CSU' named entity 'SARS-CoV-1' named entity 'inflammatory response' named entity 'virus' named entity 'biologicals' named entity 'allergic' named entity 'biologic therapy' named entity 'mAb' named entity 'Treatment of patients' named entity 'Benralizumab' named entity 'anti-IgE' named entity 'Lombardy' named entity 'liver failure' named entity 'type 2' named entity 'macrophage' named entity 'Antibody' named entity 'SARS-CoV-2' named entity 'IFN' named entity 'COVID19' named entity 'omalizumab' named entity 'intensive care unit' named entity 'lymphocyte' named entity 'allergic disease' named entity 'cyclosporine' named entity 'biologicals' named entity 'type 2' named entity 'MERS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software